PhenoNet Completes Enrollment in Phase IIb Trial of PHENOGENE-1A for ALS
PhenoNet, Inc., a clinical-stage biotechnology company developing investigational therapies for neurodegenerative diseases, has announced the completion of recruitment and randomization in its Phase IIb clinical trial evaluating PHENOGENE-1A as an adjunctive treatment for patients with mild-to-moderate amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease. The company completed the enrollment milestone on August 27, 2026, marking an important step in the clinical development of its investigational therapy and moving the program toward the generation of topline clinical data.
The randomized Phase IIb study is designed to evaluate the potential of PHENOGENE-1A to address mechanisms associated with ALS progression while being administered alongside existing standards of care. The completion of recruitment means that the study population has now been established and randomized participants can continue through the planned treatment and follow-up assessments.
ALS is a progressive neurodegenerative disorder characterized by the loss of motor neurons responsible for controlling voluntary muscle movement. As the disease progresses, patients can experience increasing muscle weakness and loss of motor function, eventually affecting mobility, communication, swallowing and breathing. Despite advances in supportive care and the availability of therapies that may slow aspects of disease progression for some patients, ALS remains an area of significant unmet medical need.
PhenoNet believes PHENOGENE-1A could potentially provide an additional disease-modifying approach for patients by addressing biological processes involved in neuroinflammation and neurodegeneration.
Phase IIb Study Reaches Key Milestone
The ongoing clinical investigation is titled “A Phase IIb Randomized, Double-Blind, Placebo-Controlled, Multi-Dose Study to Evaluate the Effects of PHENOGENE-1A (Cromolyn) as an Adjuvant Treatment in Subjects with Mild-to-Moderate ALS.”
The study is being conducted at clinical sites across the United States and Europe. Its randomized, double-blind and placebo-controlled design is intended to provide a rigorous assessment of PHENOGENE-1A while reducing potential bias in the evaluation of treatment outcomes.
The company reported that recruitment progressed at a brisk pace, reflecting interest among investigators in exploring additional therapeutic approaches for ALS. Another operational milestone was reached on July 2, 2026, when the first participant completed the treatment period.
With recruitment and randomization completed on August 27, PhenoNet can now continue advancing the trial toward its planned data readout. The results are expected to provide important information about the investigational therapy’s clinical effects, safety and potential role as an adjunctive treatment.
Completion of enrollment is particularly important for a Phase IIb program because it establishes the patient population needed to evaluate the predefined clinical objectives of the study. The resulting data could help determine whether PHENOGENE-1A warrants advancement into later-stage development.
Investigational Approach Combines Cromolyn With Drug Delivery Technology
PHENOGENE-1A is based on cromolyn sodium, an established pharmaceutical compound, combined with an advanced targeted drug-delivery platform developed to improve the compound’s bioavailability.
According to PhenoNet, the delivery technology is designed to achieve therapeutically relevant concentrations of the treatment in the blood, brain and cerebrospinal fluid (CSF). The company is developing the approach to target biological mechanisms believed to contribute to neuroinflammation and neurodegeneration.
The ability to deliver a therapeutic compound to the central nervous system represents a major challenge in the development of treatments for neurological diseases. The blood-brain barrier and other physiological mechanisms can limit the amount of many medicines that reaches the brain and spinal cord.
PhenoNet’s strategy is intended to improve exposure in relevant compartments and potentially enhance the therapeutic effects of cromolyn in patients with ALS.
The company is positioning PHENOGENE-1A as a potential disease-modifying treatment rather than simply a therapy intended to manage individual symptoms. The investigational treatment is being studied as an adjunct to existing standards of care, meaning it could potentially be used alongside currently available treatment approaches rather than replacing them.
Focus on Neuroinflammation and Disease Progression
Neuroinflammation is increasingly recognized as an important component of ALS biology. In ALS, complex interactions among neurons, immune cells and supporting cells within the nervous system can contribute to an environment associated with progressive motor neuron damage.
PhenoNet is investigating whether targeting mechanisms associated with neuroinflammation and neurodegeneration could help slow the underlying progression of disease.
The company believes that intervention early in the course of ALS may be particularly important. David R. Elmaleh, Ph.D., Founder and Chairman of PhenoNet, emphasized the potential importance of beginning treatment when the first clinical signs of declining muscle function appear.
“Addressing both the triggers and progression of ALS through a multifunctional therapeutic approach may offer a new strategy for modifying the course of the disease,” Elmaleh said.
He noted that the rationale for advancing PHENOGENE-1A into Phase IIb was supported by findings from in vitro research, in vivo ALS animal models and an earlier Phase IIa clinical cohort.
The completion of enrollment therefore represents the next stage in testing whether those earlier observations can translate into meaningful clinical effects in a larger controlled study.
Earlier Research Supports Clinical Development
Before launching the Phase IIb study, PhenoNet evaluated PHENOGENE-1A through laboratory studies, animal models and an earlier clinical cohort.
The company says these investigations provided the scientific and clinical rationale for advancing the program into its current Phase IIb stage. While preclinical studies can help establish biological activity and provide information about potential mechanisms, controlled clinical trials remain essential for determining whether an investigational therapy can safely and effectively benefit patients.
The Phase IIb trial is therefore expected to provide a more comprehensive assessment of PHENOGENE-1A in individuals with mild-to-moderate ALS.
The study’s randomized and placebo-controlled design should allow researchers to compare outcomes between participants receiving PHENOGENE-1A and those receiving placebo, while the double-blind structure is intended to reduce bias among participants and investigators.
Safety Monitoring Continues
Safety remains a key consideration as the Phase IIb trial progresses. Atul Gupta, M.D., Chief Medical Officer of PhenoNet and medical and safety monitor for the clinical program, said that no safety findings had been reported to date that resulted in a change to the study protocol or the conduct of the trial.
The study’s Safety Review Committee will continue to evaluate accumulating safety information as participants progress through the clinical program.
Gupta highlighted the need for disease-modifying therapies that can be administered alongside current standards of care and potentially address underlying disease mechanisms.
ALS remains one of the most serious diagnoses in neurology, with progressive functional decline affecting patients as well as families and caregivers. A treatment capable of safely slowing disease progression could therefore have significant implications for patients and the broader ALS community.
Clinical Investigators Highlight Potential Importance
Björn Oskarsson, M.D., a neurologist and ALS specialist at Mayo Clinic in Florida, serves as Principal Investigator for the Phase IIb study.
Oskarsson said the trial is evaluating a promising investigational approach and has the potential to contribute clinical information to the evolving ALS treatment landscape.
The Safety Review Committee will continue monitoring safety data throughout the trial as investigators gather additional information on PHENOGENE-1A.
The involvement of experienced ALS specialists and clinical investigators is an important component of the program as PhenoNet works to evaluate its investigational therapy in a population with substantial unmet medical needs.
Data Could Shape Future Development
Peter S. Conti, M.D., Ph.D., Professor of Radiology, Biomedical Engineering and Pharmaceutical Sciences at the University of Southern California, serves as a scientific advisor to PhenoNet. His expertise includes molecular imaging, pharmacology and the early diagnosis of neurodegenerative diseases.
Conti described completion of recruitment and randomization as an important milestone for PHENOGENE-1A and said the results of the Phase IIb trial could help inform the company’s future clinical and regulatory development strategy.
The topline results will be particularly important in determining whether the clinical evidence supports continued development of PHENOGENE-1A and how the company should structure subsequent studies.
A supportive outcome could potentially enable PhenoNet to advance discussions with regulators regarding a later-stage or registrational development program.
Potential Regulatory Pathway
If the Phase IIb results support further development, PhenoNet intends to engage with the U.S. Food and Drug Administration (FDA) to discuss an appropriate registrational pathway for PHENOGENE-1A.
Among the potential regulatory strategies the company plans to explore are the FDA’s 505(b)(2) pathway, a Special Protocol Assessment and orphan-drug designation.
The 505(b)(2) pathway can potentially provide a development route for certain products that rely, in part, on existing information about an approved drug or active ingredient while incorporating new clinical or other evidence. PhenoNet’s interest in this pathway is consistent with the company’s development strategy around cromolyn sodium and its targeted drug-delivery platform.
An orphan-drug designation could also potentially support development for ALS, a serious disease affecting a relatively small patient population.
However, these regulatory strategies remain subject to discussions with the FDA and would depend on the clinical data and regulatory requirements applicable to the program.
Next Stage for PHENOGENE-1A
The completion of recruitment and randomization on August 27, 2026, places PHENOGENE-1A at an important point in its clinical development. The program has progressed from preclinical research and an earlier Phase IIa cohort into a larger randomized Phase IIb investigation designed to provide additional evidence regarding efficacy and safety.
The first participant’s completion of the treatment period in July further demonstrated progress in the execution of the clinical program.
As participants continue through the study, PhenoNet will focus on collecting and analyzing the clinical data needed to determine the potential of PHENOGENE-1A as an adjunctive disease-modifying treatment for mild-to-moderate ALS.
For patients and families affected by ALS, the need for therapies capable of slowing disease progression remains substantial. PhenoNet’s approach combines an established compound with a targeted delivery strategy intended to improve exposure to therapeutically relevant compartments of the nervous system.
The forthcoming Phase IIb results will be a critical test of this approach. If the data demonstrate a favorable balance of safety and efficacy, the findings could support discussions with the FDA and help define the next phase of clinical development for PHENOGENE-1A.
For now, completion of enrollment represents a major milestone for PhenoNet as the company advances its lead program toward topline data and continues its efforts to develop new treatment options for people living with ALS.
About PhenoNet, Inc.
PhenoNet, Inc. is a privately held biotechnology company headquartered in Cambridge, Massachusetts. The company is developing PHENOGENE-1A as a potential treatment for neurodegenerative diseases, including ALS and Alzheimer’s disease (AD).
PhenoNet’s clinical-development programs are designed to address neuroinflammation and other biological mechanisms associated with neurodegeneration and disease progression. The company’s objective is to develop therapies for patients with serious diseases and substantial unmet medical needs.